Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
MENLO PARK, Calif., Feb. 04, 2016 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Leerink Partners 5th Annual Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:35 a.m. ET on Thursday, February 11, 2016, in New York. A live audio webcast and replay of the presentation will be available in the Investors section of Dermira’s corporate website at www.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, in Phase 3 development for the treatment of axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
Dermira Contact Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650.421.7200 [email protected] Investor Contact Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 [email protected]
